Comparative Pharmacology
Head-to-head clinical analysis: IDELALISIB versus PIQRAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IDELALISIB versus PIQRAY.
IDELALISIB vs PIQRAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Idelalisib is a phosphoinositide 3-kinase (PI3K) delta isoform inhibitor. It inhibits the delta isoform of PI3K, which is selectively expressed in B-cells and plays a role in B-cell activation, proliferation, and survival. By blocking PI3K delta signaling, idelalisib reduces cell proliferation and induces apoptosis in malignant B-cells.
PIQRAY (alpelisib) is a phosphatidylinositol-3-kinase (PI3K) inhibitor with inhibitory activity predominantly against PI3Kα. It inhibits the PI3K/AKT/mTOR signaling pathway, reducing cell proliferation and survival in PIK3CA-mutated cancer cells.
150 mg orally twice daily.
300 mg orally twice daily with food, taken as two 150 mg tablets.
None Documented
None Documented
Clinical Note
moderateIdelalisib + Deslanoside
"Idelalisib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateIdelalisib + Acetyldigitoxin
"Idelalisib may decrease the cardiotoxic activities of Acetyldigitoxin."
Clinical Note
moderateIdelalisib + Ouabain
"Idelalisib may decrease the cardiotoxic activities of Ouabain."
Clinical Note
moderateIdelalisib + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Idelalisib."
Terminal elimination half-life approximately 8.2 hours; supports twice-daily dosing.
The terminal elimination half-life is 12 hours (range 9-17 hours), supporting twice-daily dosing.
Primary fecal (78%) with minor renal (14% unchanged) and biliary contribution.
Following a single oral dose of [14C]-PIQRAY, 81% of the radioactivity was recovered in feces (70% unchanged) and 14% in urine (7% unchanged).
Category C
Category C
PI3K Inhibitor
PI3K Inhibitor